Yahoo TV

On today's episode of Market Domination, hosts Josh Lipton and Seana Smith break down key trading events ahead of Fourth of July.

On the pharmaceutical front, Annovis Bio (ANVS) released new data from its phase III Parkinson's study that showed cognition improvements in patients. Yahoo Finance reporter Anjalee Khemlani joins Market Domination to explain why the biotechnology company's shares are declining despite the positive trial results. Novo Nordisk (NVO) and Eli Lilly (LLY) shares are dipping in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

Wedbush Securities has increased its price target on Tesla (TSLA) to $300 from $275 per share following the automaker's second quarter vehicle delivery numbers, which beat expectations. Dan Ives, managing director and senior equity analyst at Wedbush Securities, explains why the EV maker is at a "turning point." Horizon Investments head of portfolio strategy Zach Hill also highlights which factors to watch for as companies begin releasing second quarter earnings.

Software stocks are gaining attention as investors identify potential market upside. Victor Cossel, Seaport Research Partners senior macro and equity strategist, joins Market Domination to offer guidance on navigating this sector.

This article was written by Gabriel Roy